AKTS- Aktis Oncology, Inc.

Name: Aktis Oncology, Inc. Insider Trading Data
Creator: U.S. Securities and Exchange Commission
License: https://www.sec.gov/privacy#accessibility

Aktis Oncology, Inc. (AKTS) has 10 insiders with recent SEC Form 4 filings, including 9 buys and 9 sells. AKTS is classified in the Biotechnology industry within the Health Care sector.

Insider Ownership

Role	Insider	Shares	Value	30d
10%	Vida Ventures Ii, LLC	5.67M	$132.95M	-
10%	Kim Helen Susan	4.86M	$113.90M	-
10%	Foley Todd	597.4K	$14.00M	-
COO	Ron-Bigger Shulamit	34.2K	$801.6K	-
Dir	Segal Lloyd Mitchell	19.6K	$460.2K	-

Activity

Buys and sells only

Transactions

10 filings

Date	Insider	Role	Type	Shares	Price	Value	Chg%	3M	12M
Jul 20, 2026	Herrmann Ken	Director	Sale+OE	4,856	$24.56	$119,274.04	-78.2%	-	-
Jul 17, 2026	Herrmann Ken	Director	Sale+OE	3,065	$25.21	$77,258.54	-100%	-	-
Jul 8, 2026	Czibere Akos	Chief Medical Officer	Sale+OE	50,000	$27.77	$1,388,701.12	-55.8%	-	-
Jul 8, 2026	Ron-Bigger Shulamit	Chief Operating Officer	Sale+OE	50,000	$27.75	$1,387,557.78	-56.6%	-	-
Jan 12, 2026	Kim Helen Susan	Director, 10% Owner	Buy	835,000	$18.00	$15,030,000.00	+16.7%	-22.4%	-
Jan 12, 2026	Mpm Bioventures 2018, L.P.54	10% Owner	Buy	1,112,777	$18.00	$20,029,986.00	+12.2%	-22.4%	-
Jan 12, 2026	Foley Todd82	Director, 10% Owner	Buy	232,870	$18.00	$4,191,660.00	+5.8%	-22.4%	-
Jan 12, 2026	Ecor1 Capital, LLC75	Director	Buy	2,222,222	$18.00	$39,999,996.00	+89.8%	-22.4%	-
Jan 12, 2026	Gadicke Ansbert85	10% Owner	Buy	1,112,777	$18.00	$20,029,986.00	+12.2%	-22.4%	-
Jan 12, 2026	Vida Ventures Ii, LLC	10% Owner	Buy	835,000	$18.00	$15,030,000.00	+16.7%	-22.4%	-

Insider	Role	Shares	Value	Buys	Sells

Date	Ticker	Insider	Role	Type	Shares	Price	Value	Chg%	SEC